Screener
Aquestive Therapeutics, Inc. AQST Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Liability related to the sale of future revenue, current | 1,000 | 1,000 |
| Royalty obligations, current | 51 | — |
| Debt, current | 32 | 9,994 |
| Total current liabilities | 16,478 | 47,608 |
| Debt, long-term, net | 50,654 | 27,519 |
| Royalty obligations, net | 27,835 | 25,941 |
| Liability related to the sale of future revenue, net | 61,168 | 62,023 |
| Lease liabilities | 7,525 | 4,337 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s total current liabilities?
- Aquestive Therapeutics, Inc. (AQST) reported total current liabilities of $16.48M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s total current liabilities changed year-over-year?
- Aquestive Therapeutics, Inc.'s total current liabilities decreased by 28.8% year-over-year, from $23.16M to $16.48M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s total current liabilities has grown at a 17.7% compound annual growth rate (CAGR), from $21.1M to $47.61M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Aquestive Therapeutics, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude